Cancer Immunology, Immunotherapy

ISSN: 0340-7004

Journal Home

Journal Guideline

Cancer Immunology, Immunotherapy Q1 Unclaimed

Springer Science and Business Media Deutschland GmbH Germany
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts. Cll is especially interested in papers describing clinical trial designs and outcome regardless of whether they met their designated endpoints or not, and particularly those shedding light on immunological mechanisms. CII is affiliated with the Association for Cancer Immunotherapy (CIMT), Canadian Cancer Immunotherapy Consortium (CCIC), The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT), and Sociedad Española de Inmunologia-Grupo Española de InmunoTerapia (SEI-GEIT).CIMT: CITIM: 94% of authors who answered a survey reported that they would definitely publish or probably publish in the journal again It has an SJR impact factor of 1,663.

Cancer Immunology, Immunotherapy focuses its scope in these topics and keywords: cells, cell, t, cancer, human, immune, cd, tumor, responses, vaccine, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -


Cancer Immunology, Immunotherapy


SJR Impact factor


H Index


Total Docs (Last Year)


Total Docs (3 years)


Total Refs


Total Cites (3 years)


Citable Docs (3 years)


Cites/Doc (2 years)




No comments ... Be the first to comment!

Aims and Scope

cells, cell, t, cancer, human, immune, cd, tumor, responses, vaccine, tumorspecific, vivo, class, killer, hypersensitivity, suppressor, response, clinical, delayedtype, expression, ii, lymphoma, melanoma, monoclonal, myeloidderived, natural, patients, regulation,

Best articles by citations

Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-a2a and interleukin-2

View more

The human repertoire of antibody specificities against Thomsen-Friedenreich and Tn-carcinoma-associated antigens as defined by human monoclonal antibodies

View more

Postoperative active specific immunization in curatively resected colorectal cancer patients with a virus-modified autologous tumor cell vaccine

View more

Immunological inhibition of carcinogenesis

View more

Structure and function of ETAA16: a novel cell surface antigen in Ewing's tumours

View more

Therapeutic effect of a single peritumoural dose of IL-2 on transplanted murine breast cancer

View more

Modulation of costimulation to enhance tumor immunity

View more

Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): Can ibuprofen reduce fever and chills without compromising immune stimulation?

View more

The effect of ranitidine on cellular immunity in patients with multiple myeloma

View more

The augmentation of lymphokine-activated killer activity following pulsing of human peripheral blood mononuclear cells with recombinant human interleukin-2

View more

Generation of non-permissive basement membranes by anti-laminin antibody fragments produced by matrix-embedded gene-modified cells

View more

Selective tumoricidal effect of soluble proteoglucan extracted from the basidiomycete, Agaricus blazei Murill, mediated via natural killer cell activation and apoptosis

View more

The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines

View more

Production of a human monoclonal antibody recognising a determinant on mouse IgG2b from a patient receiving mouse monoclonal antibody for diagnostic imaging

View more

Effect of picibanil (OK432) on neutrophil-mediated antitumor activity: Implication of monocyte-derived neutrophil-activating factors

View more

Graft-versus-host disease following interleukin-2/lymphokine-activated killer (LAK) cell immunotherapy in a patient with acute myelogenous leukaemia in second complete remission: autologous LAK cells following allogeneic bone marrow transplantation a

View more

Adenoviral-mediated transfer of human wild-type p53, GM-CSF and B7-1 genes results in growth suppression and autologous anti-tumor cytotoxicity of multiple myeloma cells in vitro

View more

Susceptibility of autologous target cells to lysis by lymphokine-activated effectors from interferon-a-treated chronic myelogenous leukaemia patients

View more

Effects of lipopolysaccharide on interleukin-2-induced cytotoxic activity of murine splenocyte cultures: role of prostaglandin E2 and interferons

View more

Common variable immunodeficiency and malignancy: a report of two cases and possible explanation for the association

View more

Two-dimensional gel analysis of polypeptides from normal, preneoplastic and neoplastic mouse mammary tissues

View more

The effects of ?GalCer-induced TCRV?24'V?11+ natural killer T cells on NK cell cytotoxicity in umbilical cord blood

View more

Inhibition of interleukin-2 production by tumor cell products and by CKS-17, a synthetic retroviral envelope peptide

View more

Tumour escape: antitumour effectors too much of a good thing?

View more